Literature DB >> 12078907

The disappearance of prognostic factors in Hodgkin's disease.

D Hasenclever1.   

Abstract

The purpose of this conceptual (and somewhat provocative) article is to analyse the reasons for the disappearance of prognostic factors in Hodgkin's disease (HD) and to explore the consequences for further research from a biometrical point of view. The very concept of prognostic factors is about to resolve in HD. Prognostic factors gradually loose their predictive power as treatment is successfully adapted to the disease burden. Freedom from treatment failure and overall survival curves of patients in early, intermediate and advanced stages of HD are superimposable with the best current treatment protocols of the German Hodgkin's Lymphoma Study Group. This disappearance of prognostic factors in HD necessitates a certain conceptual remodelling. It's time to think quantitatively and bivariately, and we need to (i) synthesise existing 'prognostic' factors into a quantitative measure of disease burden or severity; (ii) develop a quantitative measure of treatment strength and (iii) relate these two quantities in nomogram curves indicating how much treatment a patient with a given disease burden requires to have, say, a 85%, 90% and perhaps 95% expected chance of cure.

Entities:  

Mesh:

Year:  2002        PMID: 12078907     DOI: 10.1093/annonc/13.s1.75

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  7 in total

1.  Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin's lymphoma.

Authors:  Alessandra Romano; Calogero Vetro; Daniela Donnarumma; Stefano Forte; Massimo Ippolito; Francesco Di Raimondo
Journal:  Haematologica       Date:  2012-06       Impact factor: 9.941

2.  Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group.

Authors:  Frank G Keller; Sharon M Castellino; Lu Chen; Qinglin Pei; Stephan D Voss; Kathleen M McCarten; Stacy L Senn; Allen B Buxton; Rizvan Bush; Louis S Constine; Cindy L Schwartz
Journal:  Cancer       Date:  2018-05-08       Impact factor: 6.860

3.  Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group.

Authors:  Cindy L Schwartz; Lu Chen; Kathleen McCarten; Suzanne Wolden; Louis S Constine; Robert E Hutchison; Pedro A de Alarcon; Frank G Keller; Kara M Kelly; Tanya A Trippet; Stephan D Voss; Debra L Friedman
Journal:  Pediatr Blood Cancer       Date:  2016-10-27       Impact factor: 3.167

Review 4.  Hodgkin lymphoma: an update on its biology with new insights into classification.

Authors:  Haresh Mani; Elaine S Jaffe
Journal:  Clin Lymphoma Myeloma       Date:  2009-06

5.  Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.

Authors:  Christine Mauz-Körholz; Judith Landman-Parker; Walentyna Balwierz; Roland A Ammann; Richard A Anderson; Andische Attarbaschi; Jörg M Bartelt; Auke Beishuizen; Sabah Boudjemaa; Michaela Cepelova; Alexander Claviez; Stephen Daw; Karin Dieckmann; Ana Fernández-Teijeiro; Alexander Fosså; Stefan Gattenlöhner; Thomas Georgi; Lisa L Hjalgrim; Andrea Hraskova; Jonas Karlén; Regine Kluge; Lars Kurch; Thiery Leblanc; Georg Mann; Francoise Montravers; Jean Pears; Tanja Pelz; Vladan Rajić; Alan D Ramsay; Dietrich Stoevesandt; Anne Uyttebroeck; Dirk Vordermark; Dieter Körholz; Dirk Hasenclever; William Hamish Wallace
Journal:  Lancet Oncol       Date:  2021-12-09       Impact factor: 54.433

6.  Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma.

Authors:  Jochen K Lennerz; Karl Hoffmann; Anna-Maria Bubolz; Davor Lessel; Claudia Welke; Nele Rüther; Andreas Viardot; Peter Möller
Journal:  Oncotarget       Date:  2015-10-06

7.  The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial.

Authors:  Alessandra Romano; Chiara Pavoni; Francesco Di Raimondo; Corrado Tarella; Simonetta Viviani; Andrea Rossi; Caterina Patti; Marco Picardi; Maria Cantonetti; Giorgio La Nasa; Livio Trentin; Silvia Bolis; Valerio Zoli; Paolo Gavarotti; Paolo Corradini; Michele Cimminiello; Corrado Schiavotto; Guido Parvis; Roberta Zanotti; Guido Gini; Andrés J M Ferreri; Piera Viero; Stephane Chauvie; Alberto Biggi; Alessandro Massimo Gianni; Andrea Gallamini; Alessandro Rambaldi
Journal:  Cancer Med       Date:  2020-11-06       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.